Question Bank › The feared thing keeps not happening

The feared thing keeps not happening

The feared thing keeps not happening: management confronts a specific live worry with current evidence running against i

Calls Tested
994
Answered YES
93
Hit Rate
9.4%
rare by design

BioLife Solutions, Inc. (BLFS) — this company's answers

NO on the Q2 2023 call 2023-08-08 F
The model's full reasoning — Q2 2023 call → NO我们根据提供的财报电话会议记录,需要判断是否存在一个具体的负面担忧,以及管理层是否用已观察到的证据进行反驳。 首先,寻找具体的担忧。在电话会议中,管理层提到了宏观逆风、生物加工行业的库存去化、中国增长放缓等。但具体到公司,有一个明显的担忧:客户库存去化导致Cell Processing消耗品需求暂时放缓。管理层明确说:“我们的最大分销商也报告了中国增长放缓,与几位同行的评论一致。由于这种库存去化和广泛的波动性,我们正在调整近期需求预测,并降低2023年指引。” 这确实是一个具体的担忧:需求下降。 但问题要求的是“一个具体的负面结果,投资者、分析师或市场担心会发生”——这里担忧的是需求放缓,且已经发生。管理层承认了这一点,并调整了指引。那么管理层是否用已观察到的证据反驳这个担忧?管理层说:“我们不认为这种环境是生物加工和生物生产的新常态,而是一个暂时的客户中断期。” 但这是观点,不是证据。管理层还提到:“我们仍然对中期和长期增长潜力充满信心。” 但这也是信心。 然而,管理层是否提供了已观察到的证据表明担忧没有实现?实际上,担忧是需求放缓,而管理层承认需求确实放缓了,并降低了指引。所以担忧正在实现。管理层没有反驳,而是承认并调整了预期。因此,不符合“管理层用已观察到的证据反驳”的条件。 另外,关于剥离冷冻柜业务,管理层说他们决定剥离,但这不是担忧,而是战略决策。 所以,整体上,担忧是需求放缓,且已经发生,管理层没有用证据反驳,而是承认了。因此答案应为NO。 但再仔细看,是否有其他担忧?分析师问到了中国暴露、库存去化持续时间等,管理层回答时提到“我们相信这正在解决”,但也是信心。没有具体证据。 因此,答案是否定的。

← Back to the full BLFS analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, is there a SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company — a worry that is live on this call, evident either because analysts keep probing it or because management itself names it as a concern others hold — AND does management push back on that worry by pointing to CURRENT, ALREADY-OBSERVED evidence from the business showing that the feared outcome is, so far, NOT materializing? Answer YES when BOTH halves come through in the transcript as one coherent dynamic, in whatever form fits the business: (1) A NAMED, COMPANY-SPECIFIC FEAR THAT IS LIVE NOW. The worry is concrete and attached to this company — for example: that demand will fall off after an unusually strong stretch; that a major customer, contract, or partner will shrink, leave, or not renew; that a competitor, new technology, or cheaper alternative will take the company's business; that a key product, franchise, or pricing level is about to erode; that recent growth is a one-time bulge that will reverse; or another identifiable adverse outcome the market has been bracing for. The fear must be visible on the call itself — analysts returning to it in their questions, or management acknowledging in its own words that this is what people are worried about — not merely a generic risk factor or ordinary caution. (2) MANAGEMENT ANSWERS WITH OBSERVED BEHAVIOR, NOT REASSURANCE. Management responds by citing things that have ALREADY HAPPENED or are happening now — customers renewing, reordering, or expanding when they were expected to leave; demand holding or growing through the period when a drop-off was predicted; the threatened product, customer, or pricing actually performing in the recent period; competitive losses that have not shown up in real accounts; the feared cliff period arriving and being cleared — described with enough concrete substance (who, what, how much, or compared to when) that the rebuttal rests on evidence from the business rather than on confidence, promises, arguments about why the fear is illogical, or projections that the future will be fine. Answer NO if no specific company-attached worry is visible on the call — a routinely healthy company fielding ordinary questions is not this. Answer NO if the fear is visible but management's response is mainly reassurance, optimism, plans, or forecasts without already-observed evidence against it. Answer NO if the evidence shows the feared outcome IS materializing and management is excusing, minimizing, or promising to fix it. Answer NO if the worry is only broad macro or industry-wide gloom with nothing specific to this company's own business. Answer NO if management concedes the fear is valid and pivots to a different story instead of countering it. Answer NO if the counter-evidence is only a single vague assertion (such as 'demand remains strong') with no concrete grounding in what has actually occurred. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
AVTR Avantor, Inc. Q2 2024 2024-07-26 C+
IFS Intercorp Financial Services Inc. Q1 2024 2024-05-14 C+
AZEK The AZEK Company Inc. Q2 2024 2024-05-08 B+
GL Globe Life Inc. Q1 2024 2024-04-23 F
MNKD MannKind Corporation Q4 2023 2024-02-27 C
NICE NICE Ltd. Q4 2023 2024-02-22 B+
TYGO Tigo Energy, Inc. Q4 2023 2024-02-14 F
MET MetLife, Inc. Q4 2023 2024-02-01 B+
BBVA Banco Bilbao Vizcaya Argentaria, S.A. Q4 2023 2024-01-30 B+
TBLA Taboola.com Ltd. Q3 2023 2023-11-08 B+
GMED Globus Medical, Inc. Q3 2023 2023-11-07 B
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
MAC The Macerich Company Q3 2023 2023-10-31 D
LNTH Lantheus Holdings, Inc. Q2 2023 2023-08-03 C+
SITM SiTime Corporation Q2 2023 2023-08-02 C+
TREX Trex Company, Inc. Q2 2023 2023-07-31 B+
REYN Reynolds Consumer Products Inc. Q1 2023 2023-05-10 C
DOCN DigitalOcean Holdings, Inc. Q1 2023 2023-05-09 C+
ULCC Frontier Group Holdings, Inc. Q1 2023 2023-05-07 C+
AKR Acadia Realty Trust Q4 2022 2023-05-06 B+
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
EPR EPR Properties Q1 2023 2023-04-27 C+
MEDP Medpace Holdings, Inc. Q1 2023 2023-04-25 B+
DKS DICK'S Sporting Goods, Inc. Q4 2022 2023-03-07 B
CRBG Corebridge Financial, Inc. Q4 2022 2023-02-22 B
POOL Pool Corporation Q4 2022 2023-02-16 C+
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
REGN Regeneron Pharmaceuticals, Inc. Q4 2022 2023-02-03 C
HBAN Huntington Bancshares Incorporated Q4 2022 2023-01-20 B
A Agilent Technologies, Inc. Q4 2022 2022-11-21 B+
PCTY Paylocity Holding Corporation Q1 2023 2022-11-05 A
TT Trane Technologies plc Q3 2022 2022-11-02 A
APOG Apogee Enterprises, Inc. Q2 2023 2022-09-20 A
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
ZBRA Zebra Technologies Corporation Q2 2022 2022-08-02 C+
LIN Linde plc Q2 2022 2022-07-28 B+
SHW The Sherwin-Williams Company Q2 2022 2022-07-27 D
JBHT J.B. Hunt Transport Services, Inc. Q2 2022 2022-07-19 C+
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
KFY Korn Ferry Q4 2022 2022-06-22 B
SE Sea Limited Q1 2022 2022-05-17 F
DCGO DocGo Inc. Q1 2022 2022-05-14 C
ZVIA Zevia PBC Q1 2022 2022-05-12 B
EGHT 8x8, Inc. Q4 2022 2022-05-10 C+
CCRN Cross Country Healthcare, Inc. Q1 2022 2022-05-04 B
ABNB Airbnb, Inc. Q1 2022 2022-05-03 B+
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
BSX Boston Scientific Corporation Q1 2022 2022-04-27 B
CCK Crown Holdings, Inc. Q1 2022 2022-04-26 C+
FR First Industrial Realty Trust, Inc. Q1 2022 2022-04-21 A
SDIG Stronghold Digital Mining, Inc. Q3 2021 2021-11-30 F
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
HSY The Hershey Company Q3 2021 2021-10-28 C
PEP PepsiCo, Inc. Q3 2021 2021-10-05 B
GDS GDS Holdings Limited Q2 2021 2021-08-17 C+
PTVE Pactiv Evergreen Inc. Q2 2021 2021-08-08 C+
SPG Simon Property Group, Inc. Q2 2021 2021-08-02 B
GLW Corning Incorporated Q2 2021 2021-07-27 B+
DOV Dover Corporation Q2 2021 2021-07-20 B+
VLRS Controladora Vuela Compañía de Aviación, Q2 2021 2021-07-16 B+
MAR Marriott International, Inc. Q2 2018 2018-08-07 B
VALE Vale S.A. Q2 2018 2018-07-26 B
FICO Fair Isaac Corporation Q3 2018 2018-07-26 C+
ORAN Orange SA Q2 2018 2018-07-26 B
KIM Kimco Realty Corporation Q2 2018 2018-07-26 B+
TRUE TrueCar, Inc. Q1 2018 2018-05-08 C
TGNA TEGNA Inc. Q1 2018 2018-05-08 B+
CVS CVS Health Corporation Q1 2018 2018-05-02 B+
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+
MIDD The Middleby Corporation Q4 2017 2018-02-28 C
SBUX Starbucks Corporation Q1 2018 2018-01-26 C
AVT Avnet, Inc. Q2 2018 2018-01-25 B
GURE Gulf Resources, Inc. Q3 2017 2017-11-14 F
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
MKTX MarketAxess Holdings Inc. Q3 2017 2017-10-25 C+
PII Polaris Inc. Q3 2017 2017-10-24 C+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BCRX BioCryst Pharmaceuticals, Inc. Q1 2017 2017-05-07 B
ICFI ICF International, Inc. Q1 2017 2017-05-06 B+
CGNT Cognyte Software Ltd. Q4 2016 2017-03-09 D
BDC Belden Inc. Q4 2016 2017-02-02 B
CAG Conagra Brands, Inc. Q2 2017 2016-12-22 C+
TGI Triumph Group, Inc. Q2 2017 2016-11-03 C+
SEM Select Medical Holdings Corporation Q1 2016 2016-05-06 C+
LPSN LivePerson, Inc. Q1 2016 2016-05-04 B
UVE Universal Insurance Holdings, Inc. Q1 2016 2016-05-03 C+
ESE ESCO Technologies Inc. Q2 2016 2016-05-03 A
VRTS Virtus Investment Partners, Inc. Q1 2016 2016-04-29 D
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
BX Blackstone Inc. Q1 2016 2016-04-21 B
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C

How the model reasoned

TGI · Q2 2017 → YESThe question is: Is there a specific negative outcome that investors/analysts/market are worried about for THIS company, live on this call, and does management push back with CURRENT, ALREADY-OBSERVED...YES The specific, company-attached fear that is live on the call is that Triumph will continue to face large performance-related charges, cash burn on development programs, and failure to stabilize margins/cash flow despite the transformation (a worry analysts repeatedly probe via questions on the $80M risk, free-cash-use guidance, 747-8/C-17/G650 headwinds, and red programs). Management directly counters it by citing already-observed evidence: Q2 operating income of $70.
ULCC · Q1 2023 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors/analysts/market have been worried about for THIS company, live on this call, AND does management push back with CURRENT, ALREADY-OB...YES The transcript shows a live, company-specific worry about pilot staffing shortages (tied to network changes and new contracts elsewhere) and customer churn/retention due to lower satisfaction scores. Management directly counters both with current evidence: pilot surplus and attrition on target for staffing, plus over 90% repeat business for retention.
HOLX · Q4 2017 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company, and does management push back on that worry by poin...YES The transcript shows a live, company-specific fear centered on Cynosure: investors and analysts are worried that the acquisition will not deliver sustainable growth, that recent sequential declines reflect a lasting salesforce collapse or competitive erosion, and that the business will continue underperforming expectations rather than turning around.

More from the question bank

Doors opening at the company's own gatesReporting the counterparty's growth as its oSecond proving already underwayNew normal declared and staffedBigger than they can carry aloneDemand arrived first, the company is growingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.